Blueprint Medicines is a top-tier, publicly-traded (BPMC) Biopharmaceutical Company focused on discovering, developing and commercializing highly-selective kinase inhibitors for genomically defined diseases. Originally funded by Third Rock Ventures, the company has built a sophisticated genomics platform and a one-of-kind annotated compound collection which is delivering a pipeline of novel therapies. In just three years, four programs have been established in genomically defined cancers and one program in the rare genetic disease space.
We are seeking an innovative, collaborative and accomplished scientist to work on a variety of computational biology and genomics projects centered on target identification and drug discovery. The individual will work on internal and external datasets, including next generation bulk and single cell sequencing data, phenotypic screening data, and will develop tools and analysis strategies to generate focused hypotheses for target identification/validation and drug discovery. A critical component of the job will be the close collaboration with internal drug discovery teams and external investigators.
WHO WE ARE:
Blueprint Medicines’ mission is to dramatically improve the lives of patients with genomically defined diseases. Our singular focus is to use our deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases to craft highly selective medicines aimed at eradicating these diseases.
We don’t think in small steps. We think in giant leaps.
We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.
We know that what each and every one of us does matters and that our success depends on our ability to work together. We believe we are at our best as a company when our employees are thriving and foster a culture that provides opportunities to grow and develop professionally, while also having fun.